HAWK and HARRIER: First prospective head-to-head trials with q12w intervals immediately after loading1
The HAWK and HARRIER trials are the first prospective head-to-head trials that included 1817 patients with wet AMD across 400 centers worldwide, that demonstrated efficacy of brolucizumab at week 48 using an innovative q12w/q8w regimen.
Learn more about the study design here.
Demonstrated
Robust vision gains2*
Outperformed aflibercept with
superior fluid resolution1,2†
Learn more→
Maintained a majority of patients on a q12w interval immediately after loading through Week 481
Learn more→
Exhibited an
overall well-tolerated safety profile1
Learn more→
Disease activity
Less patients with disease activity1
Learn more→
AMD=age-related macular degeneration; q8w=treatment every 8 weeks; q12w=treatment every 12 weeks.
*The primary efficacy endpoint for the studies was the change from baseline in BCVA at Week 48 as measured by the ETDRS Letter Score, with the primary objective to demonstrate noninferiority of Beovu® vs aflibercept.
†Secondary endpoint in HAWK and HARRIER, confirmatory analysis in HAWK only (1-sided P values for superiority of Beovu).3,4
REFERENCE
-
Summary of Product Characteristics. Novartis; 2020.
-
Dugel PU, Koh A, Ogura Y, et al; on behalf of the HAWK and HARRIER Study Investigators. HAWK and HARRIER: Phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127(1):72-123.
-
Data on file. RTH258-C001. Novartis; 2019.
-
Data on file. RTH258-C002. Novartis; 2019.
Beovu® SmPC
Rate this content:
11/20 GLOPH/BRO/0307
